EcoR1 Capital’s Alaunos Therapeutics TCRT Stock Holding History

EcoR1 Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,000	Closed	-$9.19M	–	66
2020 Q1	$9.19M	Buy	+25,000	New	+$12.9M	0.96%	28

Other funds holding TCRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital's TCRT Position: Q2 2020 in Review

EcoR1 Capital sold out of Alaunos Therapeutics (TCRT) in Q2 2020, closing a stake of 25,000 shares — an estimated $9.19M sold.

EcoR1 Capital first reported a position in TCRT in Q1 2020 and held it in 1 quarter. The position peaked at $9.19M in Q1 2020. 146 funds tracked by Wall St. Rank hold TCRT as of Q2 2020.

EcoR1 Capital reported no remaining Alaunos Therapeutics position as of Q2 2020 after selling out during the quarter.
EcoR1 Capital sold 25,000 Alaunos Therapeutics shares in Q2 2020, an estimated $9.19M.
EcoR1 Capital first reported a position in Alaunos Therapeutics in Q1 2020 and held it in 1 quarter.
EcoR1 Capital's Alaunos Therapeutics position peaked at $9.19M in Q1 2020.
146 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2020.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.